- Home
- RXRX vs HTFL Comparison
RXRX vs HTFL Comparison
Compare RXRX & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RXRX | HTFL |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | 843 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | RXRX | HTFL |
|---|---|---|
| Price | $2.98 | $24.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $7.50 | ★ $38.20 |
| AVG Volume (30 Days) | ★ 23.4M | 1.9M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $74,681,000.00 | N/A |
| Revenue This Year | $12.11 | $27.66 |
| Revenue Next Year | $82.52 | $23.55 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.92 | N/A |
| 52 Week Low | $2.77 | $20.13 |
| 52 Week High | $7.18 | $41.22 |
Technical Indicators
Market Signals| Indicator | RXRX | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 39.18 | 37.67 |
| Support Level | $2.88 | $20.27 |
| Resistance Level | $4.03 | $25.05 |
| Average True Range (ATR) | 0.19 | 1.60 |
| MACD | -0.06 | -0.27 |
| Stochastic Oscillator | 10.74 | 9.26 |
Price Performance
Historical ComparisonAbout RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
About HTFL Heartflow Inc.
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.